AlphAIAlphAI — Financial news for AI agents
scanx.tradeSEP 252 min read$RVTY

Revvity Q2FY26 Results: Organic growth hits 3%, adjusted EPS $1.41

Revvity (RVTY) reported Q2FY26 results with 3% organic growth and adjusted EPS of $1.41, exceeding guidance. Diagnostics revenue rose 11% organically, while Life Sciences declined 3%. Management raised full-year guidance, citing improved market conditions and strategic reinvestments. Total revenue is projected between $2.83B and $2.86B.

Original reporting
scanx.trade
Published Sep 25, 2026, 9:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 11:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity Q2FY26 Results: Organic growth hits 3%, adjusted EPS $1.41 — source image
Source · scanx.trade
Decision brief

The 30-second read

$RVTYBullishLow
01

Why it matters

While the earnings beat and guidance raise are positive, the information is not new, limiting actionable trading ideas.

02

Market read

Earnings recap with modest guidance lift; limited short‑term trading relevance.

03

What to watch

Backlog buildup suggests future revenue upside not captured in the current quarter.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

The article recaps Revvity's Q2 FY26 earnings, highlighting organic growth, segment performance, and an upward revision to full‑year outlook.

Company-level read

Ticker impact

$RVTYBullishMedium confidence
Context

Q2 FY26 results and raised full‑year guidance were disclosed, showing 3% organic growth and adjusted EPS $1.41.

Expected impact

Modest upside potential if investors re‑price the guidance lift.

Evidence & confidence

The numbers are already public; any price reaction will be limited to traders who missed the initial release.

Market effects

Sector

Diagnostics segment strength may benefit related life‑science equipment suppliers.

Regional

U.S. market participants may adjust exposure to RVTY, but broader market impact is limited.

Global

Minimal; the story is company‑specific.

Counterpoint

What could challenge this read

The guidance lift may be overstated given the non‑recurring tariff refunds.

Key entities

  • Company
    Revvity

    Medical diagnostics and life‑sciences equipment maker (NYSE: RVTY).

Read at source← All news

Related articles

SEP 25
$CDNAMed

Biotech Stocks At 52-Week Highs - CDNA +13%, GRAL +15%, TWST +16%, ADPT, RVTY

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

rttnews.com2 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

biospace.com3 min
SEP 9
$RVTYMed

Revvity to Acquire Human Cell Design for Metabolic Disease Drug Discovery

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.

citybiz.co2 min
SEP 9
$RVTYMed

RVTY Looks 8.1% Overvalued on GF Value™ as Acquisition Adds Grow

Revvity Inc (RVTY) plans to acquire Human Cell Design, a French biotech firm, to expand its life sciences portfolio. RVTY's stock is trading at $127.08, 8.1% above its GF Value™ of $117.51, indicating modest overvaluation. The company has a GF Score™ of 77/100, with strengths in momentum and profitability but weaknesses in growth. Insiders have been net sellers over the past year.

gurufocus.com2 min